INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: IVOB on OTCMKTS) on October 15, 2019, reporting events that occurred on October 10, 2019. The filing addresses significant changes in the company's executive leadership.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation details.
Material Changes
- Departure of Principal Officer: Kathleen Karloff resigned as Chief Executive Officer effective October 10, 2019. She will continue to serve as a director and in an operational capacity. The resignation is not due to any disagreement with the company.
- Appointment of Principal Officer: Steve Shum was appointed Chief Executive Officer effective October 10, 2019.
Guidance, Outlook, and Management Commentary
The filing details the compensation package for the new CEO, Steve Shum, which includes:
- Base Salary: $260,000 annually.
- Performance Bonus: Up to $75,000 contingent upon a successful up-listing to the NASDAQ exchange. Additional bonuses are at the Board's discretion.
- Equity Grant: 400,000 shares of common stock.
- Stock Options: A three-year option to purchase 6,483,171 shares at an exercise price of $0.255 per share, vesting monthly over three years.
Mr. Shum previously served as interim CEO and CFO of Eastside Distilling, Inc., resigning from those roles to focus on INVO Bioscience.
Investor Verification Checklist
- Verify the vesting schedule and exercise terms of the 6.48 million stock options granted to the new CEO.
- Confirm the operational role Kathleen Karloff will retain post-resignation.
- Monitor the company's progress toward the NASDAQ up-listing required to trigger the $75,000 performance bonus.
- Review the company's liquidity position to ensure it can support the new executive compensation structure.